Health-related quality of life in the gender, race, and clinical experience trial.

Judith Feinberg
Department of Internal Medicine, University of Cincinnati College of Medicine

Michael Saag
Division of Infectious Disease, Department of Medicine, University of Alabama at Birmingham

Kathleen Squires
Division of Infectious Diseases and Environmental Medicine, Jefferson Medical College, Thomas Jefferson University

Judith Currier
avid Geffen School of Medicine, University of California, Los Angeles

Follow this and additional works at: https://jdc.jefferson.edu/didem

Recommended Citation
Feinberg, Judith; Saag, Michael; Squires, Kathleen; Currier, Judith; Ryan, Robert; Coate, Bruce; and Mrus, Joseph, "Health-related quality of life in the gender, race, and clinical experience trial." (2011). Division of Infectious Diseases and Environmental Medicine Faculty Papers. Paper 4.
https://jdc.jefferson.edu/didem/4
Authors
Judith Feinberg, Michael Saag, Kathleen Squires, Judith Currier, Robert Ryan, Bruce Coate, and Joseph Mrus

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/didem/4
Research Article

Health-Related Quality of Life in the Gender, Race, And Clinical Experience Trial

Judith Feinberg,1 Michael Saag,2 Kathleen Squires,3 Judith Currier,4 Robert Ryan,5 Bruce Coate,5 and Joseph Mrus6

1Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA
2Division of Infectious Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3Division of Infectious Diseases and Environmental Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107, USA
4David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90035, USA
5Medical Affairs Biometrics, Tibotec Inc., Titusville, NJ 08560, USA
6Clinical Affairs, Tibotec Therapeutics, Titusville, NJ 08560, USA

Correspondence should be addressed to Judith Feinberg, feinbej@ucmail.uc.edu

Received 30 March 2011; Accepted 1 June 2011

1. Introduction

Improvements in antiretroviral (ARV) therapy have increased the life expectancy of patients with HIV-1 infection, and HIV is now considered a manageable chronic disease [1]. The maintenance of a high quality of life (QoL), as well as optimization of physical, emotional, and social health, is an important aspect of disease management for HIV-1–infected patients. Health-related quality of life (HRQoL) measures are used to quantify the physical and mental aspects of HIV-1 infection that can impact a patient’s overall well-being. Additionally, several studies have demonstrated a correlation between HRQoL and survival of HIV-1–infected patients [2–4], highlighting the need for monitoring and optimizing HRQoL. The GRACE (Gender, Race, And Clinical Experience) study was designed to investigate sex-based and race-based differences in outcomes with darunavir/ritonavir-(DRV/r-) based therapy in treatment-experienced patients. The primary outcomes of the GRACE study have been reported [5]. Here, we report the HRQoL results from GRACE by sex and race over 48 weeks.

2. Methods

2.1. Study Design and Patients. GRACE was a 48-week, open-label, Phase IIIb study conducted at 65 study sites across the United States, Canada, and Puerto Rico. Treatment-experienced adults (HIV-1 RNA ≥ 1000 copies/mL) received DRV/r 600/100 mg twice daily plus an appropriate ARV background regimen, chosen on the basis of resistance testing [5]. Details of the study design and the primary outcomes of the GRACE study have been reported elsewhere [5]. Human
experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of this clinical research, the research protocol was reviewed and approved by institutional review boards for all 65 study sites, and all participants provided written informed consent.

2.2. Study Evaluations. Health-related QoL was measured by the Functional Assessment of HIV Infection (FAHI) questionnaire, which contained 47 questions measuring five functional subscales [6, 7]: physical (PWB), emotional (EWB), functional and global (FGWB), and social (SWB) well-being, as well as cognitive functioning (CF). The range of possible scores for each subscale was as follows: PWB and EWB, 0 to 40; FGBW, 0 to 52; SWB, 0 to 32; CF, 0 to 12. The total FAHI score, with possible scores ranging from 0 to 176, was calculated as the sum of all five subscale values, with higher scores indicating better results. Each subject completed the FAHI questionnaire at the beginning of the study visit, before other assessments, at study entry, and at weeks 4, 12, 24, and 48 or at early withdrawal. Questionnaires completed at early withdrawal visits were not included in the analyses. The time recall period was the previous 7 days. Post hoc analyses were conducted in order to investigate factors that were associated with improvement in total FAHI score over 48 weeks.

2.3. Statistical Analyses. Analyses were performed on the observed population. Imputed values were derived for each of the five subscales of the FAHI questionnaire. Imputed values were calculated if at least 50% of the items in that subscale were present using the mean of the other items in the subscale, rounded to the nearest integer; if greater than 50% of the items in a given subscale were missing, no imputation was calculated. Results from intention-to-treat–last-observation-carried-forward analyses were similar to results obtained from the observed population and are not presented here.

In the post hoc analysis that investigated factors associated with improvement in total FAHI score, 18 covariates were evaluated using a repeated measure analysis; covariates significant at the $P < .10$ level were considered for the multivariate analysis. The multivariate analysis was performed using a forward stepwise selection with stay criteria of $P < .05$. If two or more covariates selected from the univariate analyses were highly correlated, only the most significant was considered for inclusion in the multivariate models to avoid issues with collinearity.

### 3. Results

3.1. Patient Population and Baseline Characteristics. The GRACE study enrolled 429 patients, of whom 66.9% were women, 61.5% were black, 22.4% were Hispanic, and 15.2% were white. In the intent-to-treat population, overall, 53.4% achieved virologic response (HIV RNA < 50 copies/mL; women, 50.9%; men, 58.5%; black, 48.5%; Hispanic, 61.5%; white, 60.0%) [5, 8]. In the time-to-loss of virologic response–non-virologic-failure censored analysis of the overall population that censored patients who discontinued for reasons other than virologic failure, 73.2% of patients (women, 73.0%; men, 73.5%; black, 68.8%; Hispanic, 79.7%; white, 78.0%) achieved virologic response [5, 8].

The HRQoL analysis included the 193 women (67%) and 109 men (77%) who completed the trial (Figure 1(a)). By race, 178 black (67.4%), 73 Hispanic (76.0%), and 48 white (73.8%) patients completed the trial (Figure 1(b)). Women had a higher rate of discontinuation compared with men, mostly due to reasons other than virologic failure, and black patients had a higher rate of discontinuation compared with Hispanic and white patients, mostly due to loss to followup and other reasons (Figures 1(a) and 1(b)).

At baseline, women were younger and had a higher average body mass index than men (Table 1). Men and black patients had more advanced disease at baseline than women and Hispanic or white patients, respectively, with lower median CD4+ counts and higher proportions of US Centers for Disease Control and Prevention Class C disease (Table 1). Four patients who self-identified as Asian or other race were not included in the analyses by race due to their low numbers.

3.2. Health-Related Quality of Life: Total Functional Assessment of HIV Infection Score. At baseline, the total FAHI scores for the overall population ranged from 26 to 176. Women had slightly lower total FAHI scores compared with men (116.8 versus 120.8), and Hispanic patients had slightly lower total scores compared with black or white patients (114.1, 119.5, and 119.5, resp.; Figure 2); neither sex-based nor race-based differences in baseline scores were statistically significant. The total FAHI score of the entire GRACE population improved significantly by Week 4 (Figure 2(a)). Near-maximum changes were achieved by Week 12 and were maintained through Week 48. Similar patterns of improvement were observed for both sexes and all races (Figures 2(b) and 2(c)). Women demonstrated larger improvements in total FAHI scores compared with men, and black patients demonstrated larger improvements compared with Hispanic and white patients. Overall, only 3% of the subscales were imputed for missing data.

The post hoc repeated measure analysis to investigate factors associated with improved FAHI over 48 weeks identified five factors with $P < .10$ (Table 2) that were considered for the multivariate analysis. The post hoc multivariate analysis subsequently identified lower baseline FAHI score, lower baseline CD4+ cell count, confirmed virologic response, and analysis time point as significantly associated with improvement in FAHI score over 48 weeks (Table 3). Notably, neither sex nor race was found to be significant in the final model, and there was no interaction between the two variables.

In a post hoc sensitivity analysis, it was noted that patients with lower baseline FAHI scores were significantly more likely to discontinue ($P = .044$) than patients with higher baseline HRQoL scores. To assess the impact of discontinuations, an additional post hoc sensitivity analysis evaluated only patients who completed the trial. When patients who discontinued the trial were excluded and only patients who completed the trial were analyzed, the
Patients receiving treatment \((N = 429)\)

**Women** \((n = 287; 66.9\%\))
- Discontinued: 94 (32.8\%)
  - Lost to followup: 33 (11.5\%)
  - Adverse events: 24 (8.4\%)
  - withdrew consent: 13 (4.5\%)
  - Noncompliance: 13 (4.5\%)
  - Virologic failure: 10 (3.3\%)
  - Other: 10 (3.3\%)
  - (I) Pregnant: 1
  - (b) Ineligible to continue: 1
  - (c) Did not attend visits: 1
  - (d) Clinical decision: 1
  - (f) No decrease in viral load: 1
  - (g) Time restraints on visits: 1
  - (i) Sponsor’s decision: 1
- Completed: 193 (67.2\%)
  - (I) Lost to followup: 24 (8.4\%)
  - Adverse events: 22 (7.7\%)
  - Withdrew consent: 13 (4.5\%)
  - Noncompliance: 13 (4.5\%)
  - Virologic failure: 6 (2.1\%)
  - Other: 16 (5.6\%)
  - (a) Pregnant: 1
  - (b) Ineligible to continue: 2
  - (c) Did not attend visits: 2
  - (d) Patient moved: 2
  - (e) Did not attend visits: 2
  - (f) Sponsor’s decision: 1
  - (g) Time restraints on visits: 1
  - (j) Started a new ARV regimen: 1

**Men** \((n = 142; 33.1\%\))
- Discontinued: 33 (23.2\%)
  - Lost to followup: 9 (6.3\%)
  - Adverse events: 6 (4.2\%)
  - Withdrew consent: 6 (4.2\%)
  - Noncompliance: 6 (4.2\%)
  - Virologic failure: 4 (2.8\%)
  - Other: 2 (1.4%)
  - (a) Ineligible to continue: 1
  - (b) Site closed: 1
- Completed: 109 (76.8\%)
  - (I) Lost to followup: 24 (9.1%)
  - Adverse events: 17 (6.4%)
  - Withdrew consent: 12 (4.5%)
  - Noncompliance: 13 (4.9%)
  - Virologic failure: 7 (2.7%)
  - Other: 13 (4.9%)
  - (a) Site closed: 4
  - (b) Patient moved: 2
  - (c) Did not attend visits: 1
  - (d) Ineligible to continue: 1
  - (e) Safety: 4
  - (f) No decrease in viral load: 1
  - (g) Time restraints on visits: 1
  - (h) Started a new ARV regimen: 1
  - (i) Sponsor’s decision: 1

Patients excluded from analysis
\(\text{(self-identified as Asian or Other)}\)
\((n = 4)\)

- Black (n = 264; 61.5%)
  - Discontinued: 86 (32.6%)
    - Lost to followup: 24 (9.1%)
    - Adverse events: 17 (6.4%)
    - Withdrew consent: 13 (4.9%)
    - Noncompliance: 13 (4.9%)
    - Virologic failure: 7 (2.7%)
    - Other: 13 (4.9%)
      - (a) Pregnant: 1
      - (b) Ineligible to continue: 1
      - (c) Did not attend visits: 1
      - (d) Patient moved: 2
      - (e) Safety: 4
      - (f) No decrease in viral load: 1
      - (g) Time restraints on visits: 1
      - (i) Sponsor’s decision: 1
  - Completed: 178 (67.4%)
- White (n = 65; 15.2%)
  - Discontinued: 17 (26.2%)
    - Lost to followup: 5 (7.7%)
    - Adverse events: 5 (7.7%)
    - Withdrew consent: 3 (4.6%)
    - Noncompliance: 4 (6.3%)
    - Virologic failure: 2 (3.1%)
    - Other: 4 (6.3%)
      - (a) Pregnant: 1
      - (b) Ineligible to continue: 1
      - (c) Did not attend visits: 1
      - (d) Patient moved: 2
      - (e) Safety: 4
      - (f) No decrease in viral load: 1
      - (g) Time restraints on visits: 1
      - (i) Sponsor’s decision: 1
  - Completed: 48 (73.8%)
- Hispanic (n = 96; 22.4%)
  - Discontinued: 23 (24.2%)
    - Lost to followup: 9 (9.1%)
    - Adverse events: 6 (6.3%)
    - Withdrew consent: 6 (6.3%)
    - Noncompliance: 6 (6.3%)
    - Virologic failure: 4 (4.2%)
    - Other: 4 (4.2%)
      - (a) Pregnant: 1
      - (b) Ineligible to continue: 1
      - (c) Did not attend visits: 1
      - (d) Patient moved: 2
      - (e) Safety: 4
      - (f) No decrease in viral load: 1
      - (g) Time restraints on visits: 1
      - (i) Sponsor’s decision: 1
  - Completed: 73 (76.0%)

Figure 1: Study disposition by (a) sex and (b) race. **“Other” classification was selected by the investigator as reason for discontinuation.**

\(\text{bOlder patient taking too many concomitant medications; ARV: antiretroviral.}\)
Table 1: Baseline demographics and disease characteristics by sex and race.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Women (n = 287)</th>
<th>Men (n = 142)</th>
<th>Black (n = 264)</th>
<th>Hispanic (n = 96)</th>
<th>White (n = 65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SE), years</td>
<td>41.7 (0.63)</td>
<td>45.2 (0.75)</td>
<td>43.0 (0.62)</td>
<td>40.3 (1.05)</td>
<td>45.5 (1.13)</td>
</tr>
<tr>
<td>Gender, n (%) females</td>
<td>287 (100)</td>
<td>—</td>
<td>191 (72.3)</td>
<td>60 (62.5)</td>
<td>34 (52.3)</td>
</tr>
<tr>
<td>Male</td>
<td>—</td>
<td>142 (100)</td>
<td>73 (27.7)</td>
<td>36 (37.5)</td>
<td>31 (47.7)</td>
</tr>
<tr>
<td>BMI, mean (SE), kg/m²</td>
<td>28.2 (0.44)</td>
<td>25.4 (0.42)</td>
<td>27.6 (0.44)</td>
<td>26.8 (0.58)</td>
<td>26.7 (0.88)</td>
</tr>
<tr>
<td>Duration of infection, mean (SE), years</td>
<td>10.9 (0.32)</td>
<td>12.2 (0.49)</td>
<td>11.0 (0.34)</td>
<td>10.5 (0.58)</td>
<td>13.8 (0.66)</td>
</tr>
<tr>
<td>Viral load, mean (SE), log_{10} copies/mL</td>
<td>4.65 (0.05)</td>
<td>4.73 (0.07)</td>
<td>4.66 (0.06)</td>
<td>4.68 (0.09)</td>
<td>4.73 (0.10)</td>
</tr>
<tr>
<td>CD4+ count, median (range), cells/mm³</td>
<td>210 (1,868)</td>
<td>175 (2,1125)</td>
<td>179 (1,868)</td>
<td>208 (1,1125)</td>
<td>249 (6,826)</td>
</tr>
<tr>
<td>CDC Class C, n (%)</td>
<td>102 (35.5)</td>
<td>67 (47.2)</td>
<td>111 (42.0)</td>
<td>33 (34.4)</td>
<td>22 (33.8)</td>
</tr>
<tr>
<td>Prior use of ≥2 PIs, n (%)</td>
<td>168 (58.5)</td>
<td>92 (64.8)</td>
<td>156 (59.1)</td>
<td>60 (62.5)</td>
<td>42 (64.6)</td>
</tr>
<tr>
<td>PSS of the OBR, mean (SD)</td>
<td>2.0 (0.65)</td>
<td>2.0 (0.81)</td>
<td>2.0 (0.72)</td>
<td>1.9 (0.67)</td>
<td>2.0 (0.67)</td>
</tr>
<tr>
<td>Hepatitis B surface antigen (positive), n (%)</td>
<td>12 (4.2)</td>
<td>7 (4.9)</td>
<td>15 (5.7)</td>
<td>3 (3.1)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Hepatitis C antibody (positive), n (%)</td>
<td>39 (13.6)</td>
<td>25 (17.6)</td>
<td>41 (15.5)</td>
<td>12 (12.5)</td>
<td>11 (16.9)</td>
</tr>
</tbody>
</table>

Two women and two men self-identified as Asian or other and were not included in the analysis by race. By virco TYPE; SE: standard error; BMI: body mass index; CDC: Centers for Disease Control and Prevention; PI: protease inhibitor; PSS: phenotypic susceptibility score; OBR: optimized background regimen; SD: standard deviation.

Table 2: Results from the univariate analysis to investigate factors associated with improvements in total FAHI score over 48 weeks.

<table>
<thead>
<tr>
<th>Covariate</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline FAHI</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Baseline CD4+ count</td>
<td>.0052</td>
</tr>
<tr>
<td>Confirmed virologic response</td>
<td>.0335</td>
</tr>
<tr>
<td>History of psychological illness</td>
<td>.0570</td>
</tr>
<tr>
<td>Baseline log_{10} viral load</td>
<td>.0862</td>
</tr>
<tr>
<td>Stage of HIV infection</td>
<td>.1441</td>
</tr>
<tr>
<td>Sex</td>
<td>.1979</td>
</tr>
<tr>
<td>Presence of etravirine in the OBR</td>
<td>.2062</td>
</tr>
<tr>
<td>Alcohol use</td>
<td>.2700</td>
</tr>
<tr>
<td>Duration of diagnosis</td>
<td>.2995</td>
</tr>
<tr>
<td>Black race versus other</td>
<td>.3490</td>
</tr>
<tr>
<td>Incidence of grade 2–4 AE</td>
<td>.4374</td>
</tr>
<tr>
<td>Smoker</td>
<td>.5272</td>
</tr>
<tr>
<td>Presence of hepatitis C antibody</td>
<td>.5938</td>
</tr>
<tr>
<td>Age</td>
<td>.7183</td>
</tr>
<tr>
<td>Structured treatment interruption</td>
<td>.7757</td>
</tr>
<tr>
<td>Adherence</td>
<td>.8049</td>
</tr>
<tr>
<td>Drug use</td>
<td>.9548</td>
</tr>
</tbody>
</table>

FAHI: Functional Assessment of HIV Infection; OBR: optimized background regimen; AE: adverse event.

3.3 Health-Related Quality of Life: Functional Assessment of HIV Infection Subscales. The EWB and PWB subscales showed significant changes from baseline to Week 12, which were maintained through Week 48 for the overall population and across all sex and race subgroups (Table 4). Women and black patients demonstrated the largest changes in EWB compared with the other subgroups. The FGWB and SWB subscales showed small improvements from baseline through Week 48 overall. Changes in the FGWB subscale were only significant for women and black patients (Table 4). The CF subscale values did not change over 48 weeks for the overall population, or for any of the sex and race subgroups.

4. Discussion

Many factors can impact the HRQoL of patients with HIV-1, including the tolerability of different ARV agents. Differences in safety/tolerability, pharmacokinetic parameters, and/or efficacy of ARVs could potentially contribute to sex-based or race-based differences in HRQoL scores. To date, studies investigating sex-based and race-based differences in HRQoL for HIV-1–infected patients have reported conflicting results [9–12]. In the GRACE study, HRQoL significantly improved for all participants. Near-maximal improvements were reached by Week 12 and were maintained through Week 48. When only patients who completed the trial were analyzed, similar improvements in total FAHI score over time were still seen, suggesting that the improvements in the overall...
population were not an artifact of patients with low HRQoL scores discontinuing the trial.

All sex and racial/ethnic groups demonstrated improvements in HRQoL over 48 weeks. These results are consistent with those from a previous study of 1178 patients receiving ARV therapy, which also showed that HRQoL improved over time, regardless of sex [11]. In univariate assessments, the largest improvements in total FAHI scores were seen in women and black patients, despite the fact that these two groups both had lower virologic response rates and higher discontinuation rates compared with men and with Hispanic and white patients, respectively. The differences seen here in total FAHI scores were driven by the larger increases in the EWB and FGWB subscales for women and black patients compared with the other subgroups. The post hoc multivariate analysis, however, found that neither black race nor sex was significantly associated with improved total FAHI scores over 48 weeks. Given that sex and race were not associated with improved total FAHI in the multivariate analysis, it is likely that differences in the change in HRQoL by sex and race were at least partially driven by differences in baseline characteristics, such as disease severity. These results are in agreement with those from another study of 287 HIV-1–infected women who completed a HRQoL assessment.
Table 4: Mean change from baseline in FAHI questionnaire subscales (observed*).

<table>
<thead>
<tr>
<th></th>
<th>Overall</th>
<th>Women</th>
<th>Men</th>
<th>Black</th>
<th>Hispanic</th>
<th>White</th>
</tr>
</thead>
<tbody>
<tr>
<td>PWB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>424</td>
<td>29.4</td>
<td>283</td>
<td>141</td>
<td>39.6</td>
<td>262</td>
</tr>
<tr>
<td>Wk 12Δ</td>
<td>359</td>
<td>2.6b</td>
<td>236</td>
<td>123</td>
<td>2.3b</td>
<td>218</td>
</tr>
<tr>
<td>Wk 48Δ</td>
<td>298</td>
<td>2.2b</td>
<td>190</td>
<td>108</td>
<td>2.0b</td>
<td>176</td>
</tr>
<tr>
<td>EWB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>423</td>
<td>25.1</td>
<td>283</td>
<td>140</td>
<td>29.6</td>
<td>265</td>
</tr>
<tr>
<td>Wk 12Δ</td>
<td>358</td>
<td>3.1b</td>
<td>235</td>
<td>123</td>
<td>2.2b</td>
<td>218</td>
</tr>
<tr>
<td>Wk 48Δ</td>
<td>297</td>
<td>3.8b</td>
<td>190</td>
<td>107</td>
<td>2.5b</td>
<td>175</td>
</tr>
<tr>
<td>SWB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>423</td>
<td>20.5</td>
<td>283</td>
<td>140</td>
<td>26.5</td>
<td>261</td>
</tr>
<tr>
<td>Wk 12Δ</td>
<td>359</td>
<td>0.2</td>
<td>236</td>
<td>123</td>
<td>-0.2</td>
<td>218</td>
</tr>
<tr>
<td>Wk 48Δ</td>
<td>296</td>
<td>-0.1</td>
<td>189</td>
<td>107</td>
<td>-0.4</td>
<td>174</td>
</tr>
<tr>
<td>CF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>423</td>
<td>8.2</td>
<td>283</td>
<td>8.0</td>
<td>140</td>
<td>107</td>
</tr>
<tr>
<td>Wk 12Δ</td>
<td>359</td>
<td>0.1</td>
<td>236</td>
<td>0.3</td>
<td>-0.2</td>
<td>218</td>
</tr>
<tr>
<td>Wk 48Δ</td>
<td>296</td>
<td>-0.1</td>
<td>189</td>
<td>0.1</td>
<td>-0.4</td>
<td>174</td>
</tr>
<tr>
<td>FGWB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BL</td>
<td>423</td>
<td>34.9</td>
<td>283</td>
<td>34.8</td>
<td>140</td>
<td>35.2</td>
</tr>
<tr>
<td>Wk 12Δ</td>
<td>359</td>
<td>1.1b</td>
<td>236</td>
<td>1.4b</td>
<td>123</td>
<td>0.6</td>
</tr>
<tr>
<td>Wk 48Δ</td>
<td>297</td>
<td>0.7</td>
<td>190</td>
<td>1.0</td>
<td>107</td>
<td>0.3</td>
</tr>
</tbody>
</table>

*The $n$ value varies for each parameter. bSignificant change ($P < .05$); FAHI: Functional Assessment of HIV Infection; PWB: physical well-being; BL: baseline; Wk: week; Δ: change from baseline; EWB: emotional well-being; SWB: social well-being; CF: cognitive functioning; FGWB: functional and global well-being.

during their current treatment regimen. This study also found that race had no bearing on HRQoL [10]; however, changes in HRQoL over time were not assessed.

Lower baseline FAHI scores, lower baseline CD4+ cell counts, and confirmed virologic response were identified as significantly associated with improved total FAHI scores over 48 weeks. CD4+ cell count and general disease state have previously been associated with absolute HRQoL scores in other studies [10, 12, 13]. Higher CD4+ cell counts have been linked to higher HRQoL scores in women and men [10, 13], whereas the presence of AIDS has been linked to lower self-perceived physical health scores in both sexes [12]. The DUET study, which investigated the efficacy and safety of etravirine in treatment-experienced patients, also demonstrated an association between baseline FAHI score and CD4+ cell counts and improvement in FAHI scores over 24 weeks [14].

Results from this study suggest that DRV/r-based, optimized, ARV therapy over 48 weeks results in significant improvement in self-perceived HRQoL, regardless of sex and race. However, due to the single-arm design of this study, we cannot conclude whether this improvement is better or worse than those associated with other ARV regimens. Previous studies of sex-based and race-based differences in HRQoL scores have demonstrated conflicting results, with some studies noting differences in overall HRQoL between the sexes or races and other studies reporting no differences [9–12]. These studies, however, are limited due to low proportions of women or people of color and/or the enrollment of women only, with no male group for comparison. In contrast, the large proportion of women enrolled in GRACE, along with a sufficient number of men and the large proportion of people of color, may allow more clinically meaningful conclusions to be drawn regarding sex-based and race-based differences in HRQoL.

Although the overall conclusions from previous studies about sex-based or race-based differences in HRQoL are contradictory, previous studies do suggest that factors affecting HRQoL scores may vary between sexes. One study showed that longer duration of infection and low levels of social support were linked to lower HRQoL scores in women, whereas difficulty taking ARV tablets, intravenous drug use, and low levels of social support were associated with lower HRQoL scores in men [12]. These sex-associated differences may make it possible to tailor HIV treatments and treatment support to women and men, thus maximizing their overall QoL.

In this trial, confirmed virologic response was found to be significantly associated with improved total FAHI scores. In the GRACE trial, women and black patients had lower response rates and higher discontinuation rates than the other sex and race subgroups [5]. Based on this, lower improvements in FAHI scores in these two groups may have been expected. However, the opposite was observed, with women and black patients demonstrating the largest improvements in FAHI scores over 48 weeks. These contrary results suggest the need to measure alternative outcomes in clinical trials, as virologic response alone may not be
whole indicative of a patient's overall improvement while on ARV therapy. The GRACE study was designed with patient support in mind, with opportunities to apply for sponsorship for site-specific recruitment and retention activities [15]. These activities may have contributed to the subjects' comfort level with both treatment and study participation and may have led to a greater sense of attachment to site staff and care delivery. It is likely that factors distinct from virologic response may be influencing patients' overall HRQoL, particularly for women and black patients, and these should be investigated in the future.

Interestingly, we found that patients with lower baseline FAHI scores were significantly more likely to discontinue than patients with higher baseline HRQoL scores. Although data are lacking with regard to the association between HRQoL and retention of patients in clinical trials, other studies have linked lower HRQoL scores to decreased survival of HIV-1–infected subjects [2–4]. Furthermore, measures of HRQoL in a large veteran outpatient population have also been shown to predict survival more generally [16]. In the future, it may be possible to identify patients with a higher risk of discontinuation based on their baseline HRQoL scores; these patients could then be more closely monitored, potentially improving retention in care. This approach deserves further study.

5. Conclusions

The sex-based and race-based differences in the improvements in total FAHI score and FAHI subscales may provide insight into the subtly different effects of HIV-1 infection and treatment on HRQoL in different populations. The data from GRACE on HRQoL by sex and race may provide valuable information into methods resulting in future optimization of treatments and retention in care for specific populations of HIV-infected patients.

Acknowledgments

J. Currier has received research grants from Tibotec, Merck, Schering-Plough, and Theratechnologies, acted as an advisor for Tibotec, Bristol-Myers Squibb, Merck, and GlaxoSmithKline, and received honoraria from GlaxoSmithKline. K. Squires has received grant/research support from Biocryst, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and Viiv, acted as a consultant for GlaxoSmithKline and Merck, been an advisory board member for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and Tobira, and is a DSBM member with Pfizer. J. Feinberg has received grant support from Tibotec, Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer and served as a speaker and/or consultant for Tibotec, Bristol-Myers Squibb, Merck, GlaxoSmithKline, and Pfizer. M. Saag has received research grant support from Tibotec, Bristol-Myers Squibb, Merck, Boehringer Ingelheim, Viiv, and Gilead and acted as a consultant/investigator for Tibotec, Bristol-Myers Squibb, Merck, Boehringer Ingelheim, Viiv, and Gilead. B. Coate and R. Ryan are employees of Tibotec Inc. J. Mrus is an employee of Tibotec Therapeutics. The authors would like to thank the patients and their families, the staff and principal investigators, and the study sites for their participation in the trial. The authors would like to acknowledge Gilead for supplying emtricitabine, tenofovir disoproxil fumarate, and emtricitabine/tenofovir disoproxil fumarate. The authors would additionally like to acknowledge internal study support staff, as well as Cali Howitt, Ph.D., Medicus International New York, for her editorial assistance.

References


